A recent study suggests that medications like Ozempic and Wegovy may have the potential to alleviate symptoms of anxiety and depression. Both Wegovy, a weight-loss injection, and Ozempic, a type 2 diabetes treatment, contain the active ingredient semaglutide, categorized as a GLP-1 receptor agonist.
An international team of researchers investigated the effects of these medications on mental health conditions by analyzing data from health registries in Sweden. They focused on individuals diagnosed with anxiety or depression who were also receiving anti-diabetic medication between 2009 and 2022. The study included data from over 95,000 patients, with 22,480 using GLP-1s.
According to the findings published in The Lancet Psychiatry, semaglutide and liraglutide, also known as Saxenda, were associated with a reduced risk of deteriorating mental health compared to not using this class of medication. Semaglutide particularly showed a 44% lower risk of worsening depression and a 38% lower risk of worsening anxiety, as well as a decreased risk of substance abuse.
The study authors from various institutions highlighted that semaglutide and liraglutide could be beneficial therapeutic options for individuals dealing with anxiety, depression, diabetes, and obesity. However, the exact mechanisms behind the mood-improving effects of these medications remain unclear.
In a separate study, Danish researchers explored the impact of GLP-1 receptor agonists on pre-term birth risk in pregnant individuals using these medications for diabetes management or weight reduction. The study, covering 480,231 women and 756,636 pregnancies, found a higher risk of pre-term birth associated with GLP-1 receptor agonists when used for diabetes treatment but not for weight management. This suggests that the underlying diabetes condition, rather than the medication itself, may be the contributing factor to pre-term birth risk.
The studies shed light on the potential dual benefits of semaglutide and liraglutide in managing mental health conditions and pregnancy outcomes, offering promising avenues for further research and clinical applications.
(Note: The article has been rewritten for clarity and optimization without changing any facts.)